Skip to main content
. 2020 Feb 4;20:30. doi: 10.1186/s12876-020-1180-0

Table 2.

Laboratory tests including blood routine examination and clinical biochemistry at the time of baseline evaluation

Variables PAs-HSOS BCS
ALT < 3× ULN, n/N (%) 64.36%(65/101) 94.74%(54/57)
ALT 3–8 × ULN, n/N (%) 21.78%(22/101) 3.51%(2/57)
ALT > 8 × ULN, n/N (%) 13.86%(14/101) 1.75%(1/57)
AST < 3 × ULN, n/N (%) 55.88%(57/102) 91.23%(52/57)
AST 3–8 × ULN, n/N (%) 35.29%(36/102) 8.77%(5/57)
AST > 8 × ULN, n/N (%) 8.82%(9/102) 0
T-BIL <34.2 μmol/L 52.94% (54/102) 61.40% (35/57)
T-BIL 34.2–85.5 μmol/L, n/N(%) 81.37% (83/102) 33.33% (19/57)
T-BIL 85.5–136.8 μmol/L, n/N(%) 7.84%(8/102) 1.75%(1/57)
T-BIL > 136.8 μmol/L, n/N(%) 10.78%(11/102) 3.52%(2/57)
Cr < 1× ULN, n/N(%) 79.52%(66/83) 96.55%(56/58)
Cr 1–2 × ULN, n/N(%) 18.07%(15/83) 3.45%(2/58)
Cr > 2× ULN,n/N(%) 2.41%(2/83) 0

PAs-HSOS pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome, BCS Budd-Chiari syndrome, ALT alanine aminotransferase, AST aspartate aminotransferase, T-BIL total bilirubin, Cr creatinine, ULN upper limit of normal, LLN lower limit of normal